Business
OncBioMune to Present at 18th Annual BIO CEO & Investors Conference
OncBioMune to Present at 18th Annual BIO CEO & Investors Conference.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune to Present at 18th Annual BIO CEO & Investors Conference \n\nOncBioMune to Present at 18th Annual BIO CEO & Investors Conference\n\n\n BATON ROUGE, LA--(Marketwired - January 25, 2016) -  OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company will be presenting at the 18th Annual BIO CEO & Investor Conference being held February 8-9, 2016 at the Waldorf Astoria in New York City. Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will be presenting at 3:30 PM ET on Tuesday, February 9 in the Duke of Windsor room during the conference's Oncology Track. The presentation will include a corporate overview that includes the latest data from the ongoing Phase 1 clinical trial of ProscaVax for prostate cancer; information on the Phase 2 trial of ProscaVax planned for the first half of 2016; and other clinical and business developments. The presentation will be webcast and available on the \"Investors\" section of the OncBioMune website (www.OncBioMune.com) following the live presentation.Additionally, OncBioMune management will be available for individual meetings with conference attendees. Interested parties can contact OncBioMune to arrange a meeting at: https://oncbiomunepharmaceuticalsinc.partnering.bio.org/inova-business-platform/webclient/#/bio/1300/home?_ga=1.208899035.830712129.1443542113 or by contacting Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune at: [email protected] up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/\n About OncBioMune Pharmaceuticals, Inc.\n OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in early 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.This press release does not constitute ...